Ship inhibitors and uses thereof

A pharmaceutical composition comprising a SHIP inhibitor compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein formula (I) is as follows:

• wherein
• R1 is methyl;
• R2 is methyl;
• R3 is hydrogen, hydroxyl, substituted amino, and aminoalkyl;
• R4 is hydrogen, hydroxy, substituted amino, unsubstituted amino, and aminoalkyl;
• R5 is hydrogen;
• R13 is hydrogen;
• X1 is selected from the group consisting of hydrogen, unsubstituted amino, and aminoalkyl;
• and
• the dotted lines represent optional double bonds;
• wherein, at least one of R3, R4, or X1 is selected from unsubstituted amino, and aminoalkyl,
• wherein if a double bond exists between the 4,5 or 5,6 positions, then R13 is absent, and
• wherein said pharmaceutical composition is suitable for use in a mammal,
• with the proviso that X1 cannot be unsubstituted amino when R4 is hydrogen, wherein at least two of R3, R4 or X1 are selected from unsubstituted amino, and aminoalkyl, or wherein R3, R4, and X1 are selected from unsubstituted amino, and aminoalkyl.

A pharmaceutical composition comprising a SHIP inhibitor compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein formula (I) is as follows:

• (I)
• wherein
• R1 is methyl;
• R2 is methyl;
• R3 is hydrogen, hydroxyl, substituted amino, or aminoalkyl;
• R4 is selected from the group consisting of hydrogen, hydroxy, substituted amino, unsubstituted amino, and aminoalkyl;
• R5 is hydrogen or alkyl;
• R13 is hydrogen;
• X1 is selected from the group consisting of hydrogen, unsubstituted amino, alkyl, and aminoalkyl;
• and
• the dotted lines represent optional double bonds;
• wherein at least two of R3, R4, or X1 is selected from unsubstituted amino, and aminoalkyl;
• and
• wherein, if a double bond exists between the 4,5 or 5,6 positions, then R13 is absent, and a pharmaceutically acceptable carrier.